Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
Cristiano Bortoluzzi(Ospedale Civile di Venezia), Paolo Simioni(University of Padua), Pierpaolo Di Micco, Chiara Simion(Azienda Ospedale - Università Padova), Egidio Imbalzano(University of Messina), Giuseppe Camporese(University of Padua), E Callegari(Ca' Foncello Hospital), Davide Ceccato(Azienda Ospedale - Università Padova), Enrico Bernardi(Amsterdam UMC Location University of Amsterdam), Ngoc Vo Hong(Ospedale San Paolo), Franco Noventa(University of Padua), Chiara Tonello(University of Padua), Elena Campello(University of Padua)
Cited by 5
Related Papers
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
|Blood|2002|1.9k
Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
|Gastroenterology|1997|1.4k
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
|Journal of Thrombosis and Haemostasis|2010|1.2k
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
|Haematologica|2007|774
COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure
|Thrombosis and Haemostasis|2020|738